Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.
This combination of email and password didn't match our records. Your account might not be activated. If so, please click on the link we sent you via email. You can also request a password reset or a new activation email using the links below.
4Q'25 vs. 4Q'24 Results Sales: € 1.446 Bn (+6.2% vs. +2.7% BS(e) and +2.9% consensus); FY2025 vs. FY2024 Results Sales: € 5.042 Bn (+5.3% vs. +4.3% BS(e) and +4.3% consensus); Adjusted EBITDA: € 1.045 Bn (+7.8% vs. +5.2% BS(e) and +5.1% consensus); EBIT: € 834.46 M (+36.3% vs. +30.7% BS(e) and +28.9% consensus); Net Profit: € 593.7 M (+11.8% vs. +14.3% BS(e) and +12.8% consensus);
De la Conference call de Rdos. 2025 destacamos los siguientes mensajes:
IDEAS DE VALOR RELATIVO: ABRIMOS EL RELATIVO LARGO BANCOS VS QUÍMICAS STOXX 600 (ANÁLISIS BANCO SABADELL)
FY2025 vs. FY2024 Results EBITDA: € 5.334 Bn (-0.6% vs. -0.4% BS(e) and +0.1% consensus); Net Profit: € 2.023 Bn (+6.4% vs. +7.5% BS(e) and +9.3% consensus);
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.